ATRIAL FIBRILLATION IN PATIENT WITH DIABETES MELLITUS 2 TYPE: CO-EXISTANCE AND THERAPEUTIC APROCHES
Abstract
On the example of the clinical case of atrial fibrillation in patient with diabetes mellitus type 2, were discussed molecular mechanisms and therapeutic perspectives, anticoagulation treatment and anti-arrhythmic treatment strategies benefit. Recommendations on lifestyle modification and medicament treatment tactics are described. Atrial fibrillation and diabetes mellitus are very common comorbidities and with high expectance they will co-exist together in the future because of the both conditions prevalence especially in older patients group. Therefore, establishing of the most effective and safe treatment it is very important to the subpopulation of patients with AF and DM. New studies with larger numbers of patients from different age and rage groups with diabetes and AF are needed to investigate the mechanisms of thisrelationship and all possible therapeutic approaches in order to determine the best possible individual management of both conditions.
Downloads
References
Tadic M. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice / M. Tadic, C. Cuspidic // Archives of Cardiovascular Diseases. –2015. – Vol.108 (4). – p. 269–276.
Martin-Timon. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? / Martin-Timon, C. Sevillano-Collantes, A. Segura-Galindo, F. J. Del Canizo-Gomez // World J Diabetes. – 2014. – No. 5. – p. 444–470.
Zhang Q. Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies / Q. Zhang, T. Liu, C.Y. Ng, G. Li // Cardiovasc Ther. – 2014. – No. 32. – p. 233–4.
Chao T.F. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose / T. F. Chao, K. Suenari, S. L. Chang, et al. // Am J Cardiol. – 2010. – No. 106. – p. 1615–1620.
Kamenov Z.A. Diabetic autonomic neuropathy / Z. A. Kamenov, L. D. Traykov // Adv Exp Med Biol. – 2012. – No. 771. – p. 176–193.
Otake H. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart / H. Otake, H. Suzuki, T. Honda, Y. Maruyama // Int Heart J.- 2009. – No. 50. - p. 627-641.
Chang S. H., Wu L. S., Chiou M. J., Liu J. R., Yu K. H., Kuo C. F., Wen M. S., Chen W. J., Yeh Y. H., See L. C. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014; 13: 123.
Fatemi O., Yuriditsky E., Tsioufis C., Tsachris D., Morgan T., Basile J., Bigger T., Cushman W., Goff D., Soliman E. Z., Thomas A., Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014; 114: 1217–1222.
Overvad T. F., Rasmussen L. H., Skjoth F., Overvad K., Lip G. Y., Larsen T. B. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013; 126:640.e649–617.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS / Paulus Kirchhof, Stefano Benussi, Anders Ahlsson et al. //European Heart Journal. – 2016. – doi:10.1093/eurheartj/ehw210.
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease/ [B. Ibanez, S. James, S. Agewall, et al.] // Circulation. – 2017. – No. 1. – p. 1–57.
Manolis A. J. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. / A. J. Manolis, E. A. Rosei, A. Coca, et al. // J Hypertens. – 2012. – No. 30. – p. 239–252.
Connolly S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. / S. Connolly, J. Pogue, R. Hart, et al. // Lancet. – 2006. – No. 367. – p. 1903–1912.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults / Paul K. Whelton, Robert M. Carey, Wilbert S. Aronow, et al. // JACC. – 2017. – doi : 10.1016/j.jacc.2017.11.006.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
